Page last updated: 2024-12-06

metflurazon

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

metflurazon: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID32011
SCHEMBL ID135108
MeSH IDM0041853

Synonyms (31)

Synonym
metflurazon
4-chloro-5-(dimethylamino)-2-[3-(trifluoromethyl)phenyl]pyridazin-3-one
4-chloro-5-(dimethylamino)-2-alpha,alpha,alpha-(trifluoro-m-tolyl)-3-(2h)-pyridazinone
4-chloro-5-dimethylamino-2-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridazin-3(2h)-one
san-6706
sandoz 6706
nt6hy78wbn ,
23576-23-0
unii-nt6hy78wbn
metflurazon [iso]
3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-(3-(trifluoromethyl)phenyl)-
san 6706-3197
S-6706 ,
1-m-trifluoromethylphenyl-4-dimethylamino-5-chloropyridaz-6-one
4-chloro-5-dimethylamino-2-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)pyridazin-3(2h)-one
methylnorflurazon
3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-
sandoz-6706
4-chloro-5-(dimethylamino)-2,3-dihydro-2-(3-(trifluoromethyl)phenyl)-3-pyridazinone
metflukazone
4-chloro-5-(dimethylamino)-2-((3-trifluoromethyl)phenyl)-3(2h)-pyridazinone
4-chloro-5-(dimethylamino)-2-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-3(2h)-pyridazinone
metflurazone
san-h-6706
SCHEMBL135108
DTXSID8042133
4-chloro-5-dimethylamino-2-[3-(trifluoromethyl)phenyl]pyridazin-3-one
4-chloro-5-(dimethylamino)-2-(3-(trifluoromethyl)phenyl)pyridazin-3(2h)-one ,
Q27285043
cyqmvkqkbffdoo-uhfffaoysa-n
AKOS040753011
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]